12:00 AM
Sep 16, 2013
 |  BC Week In Review  |  Company News  |  Other News

Teva, BASF, Par Pharmaceutical endocrine/metabolic news

The U.S. Court of Appeals for the Federal Circuit reversed in part a lower court's 2012 ruling upholding U.S. Patent Nos. 5,656,667 and 5,502,077 covering Pronova Biopharma ASA's lipid-lowering drug, Lovaza. Chemicals company BASF acquired Pronova in January. The Court of Appeals overturned the U.S. District Court for the District of Delaware's decision and invalidated the '667 patent, saying that...

Read the full 298 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >